Nearly a century after rheumatic fever (RF) and rheumatic heart disease (RHD) was eradicated from the developed world, the disease remains endemic in many low- and middle-income countries (LMICs), with grim health and socioeconomic impacts. The neglect of RHD which persisted for a semi-centennial was further driven by competing infectious diseases, particularly the human immunodeficiency virus (HIV) pandemic. However, over the last two-decades, slowly at first but with building momentum, there has been a resurgence of interest in RF/RHD. In this narrative review, we present the advances that have been made in the RF/RHD continuum over the past two decades since the re-awakening of interest, with a more concise focus on the last decade’s achievements. Such primary advances include understanding the genetic predisposition to RHD, group A Streptococcus (GAS) vaccine development, and improved diagnostic strategies for GAS pharyngitis. Echocardiographic screening for RHD has been a major advance which has unearthed the prevailing high burden of RHD and the recent demonstration of benefit of secondary antibiotic prophylaxis on halting progression of latent RHD is a major step forward. Multiple befitting advances in tertiary management of RHD have also been realized. Finally, we summarize the research gaps and provide illumination on profitable future directions towards global eradication of RHD.

As doenças cardiovasculares (DCV) e o câncer representam as maiores causas de morte no Brasil e no mundo. Tendo em vista tamanha relevância epidemiológica, o artigo “Taxas de Mortalidade por Doenças Cardiovasculares e Câncer na População Brasileira com Idade entre 35 e 74 Anos, 1996-2017”, por meio da análise dos dados de mortalidade das Estatísticas Vitais do DATASUS (Sistema de Informação de Mortalidade – SIM), apresenta o perfil de mortalidade por esses grupos de doenças, discute sua evolução entre 1996